Andrew Gwynne MP: speeches 2025

355 published records · newest first.

Speeches

4 Feb 2025 · National Cancer Plan · Hansard source
More
I congratulate the hon. Lady’s step-mum on ringing that bell, which is great news. The hon. Lady is absolutely right to raise the issue of inconsistency when it comes to the levels of service that different patients get. That will obviously be a major factor in the national cancer plan going forward, to ensure that all people diagnosed with cancer have the same levels of treatment and the same opportunities to survive.
4 Feb 2025 · National Cancer Plan · Hansard source
More
I thank the right hon. Gentleman for that suggestion and will ask my officials to look into it. I am very keen that we maximise the latest advances in technology, genomics, life sciences and research to ensure that we identify people who are at risk of cancer, preferably before they develop cancer, so that we can get them on appropriate treatments where necessary and they avoid the pain and misery that cancer can bring.
4 Feb 2025 · National Cancer Plan · Hansard source
More
My hon. Friend has my full assurance that all cancers—all tumour types—will be an integral part of the national cancer plan. On rarer cancers, it is important that we use the call for evidence and the discussions we will have in the coming weeks and months to ensure that those voices are heard as we drive forward our plan.
4 Feb 2025 · National Cancer Plan · Hansard source
More
I thank the hon. Gentleman for the work that he did in this area in a previous guise. I am more than happy to meet him and Mike Nesbitt, with whom I had a meeting on drug strategy and drugs as a public health issue before this statement, to drive forward how we can improve outcomes in Northern Ireland and get that plan working again, as it should never have stalled.
4 Feb 2025 · National Cancer Plan · Hansard source
More
My hon. Friend makes a really important point, which is not lost on those of us on the Government Front Bench. There are real challenges across the healthcare system, and some of the areas with some of the worst outcomes also happen to have some of the worst health inequalities. Those issues are exacerbated by the pressure on the healthcare system. He can have my reassurance that the Government will make it a priority to drive down health inequalities and ensure that healthcare systems get the support they need.
4 Feb 2025 · National Cancer Plan · Hansard source
More
Through my hon. Friend, I would like to pass my condolences on to Nikki for the loss of Ethan. As I have said, we have not made anything like the progress we would want to make on treatment and survival rates for brain tumours. That will form an integral part of our national cancer plan, and we will utilise all the latest advances in technology and science to try to get the better outcomes that we so desperately want.
4 Feb 2025 · National Cancer Plan · Hansard source
More
Absolutely. Things are advancing so quickly in technology and innovation. It is quite remarkable that science fiction is becoming science fact. We are obviously interested in minimally invasive therapies, and they will form part of the plan. That is why we are consulting. That is the purpose of this exercise: so that we can look at what technologies are here today, what the emerging technologies are and how they will shift the dial on some cancers.
4 Feb 2025 · National Cancer Plan · Hansard source
More
I am grateful to the hon. Gentleman for that question, and also for the written parliamentary questions about prostate cancer that he and a number of other Members have tabled. According to the current guidance, screening for prostate cancer is not recommended in the UK because of the inaccuracy of the current best test for prostate-specific antigen. Indeed, it could actually harm men, as some might be diagnosed with a cancer that would not have caused them problems during their lives. However, I am looking at this carefully, and I know that further information has gone to the National Institute for Health and Care Research so that it can, perhaps, reach a different conclusion. Obviously, as technology and other mechanisms advance, this may well be an area where we can make inroads, but I am happy to work with the hon. Gentleman to ensure that every opportunity is met.
4 Feb 2025 · National Cancer Plan · Hansard source
More
My hon. Friend makes some really important points. The need to get people scanned more quickly, and to get results to consultants, is in part why we now have extra capacity through community diagnostic centres, where there are extra facilities for scans. She is absolutely right to raise the issue of where AI and emerging technologies may take us, which will almost certainly lead to faster identification of cancers.
4 Feb 2025 · National Cancer Plan · Hansard source
More
My hon. Friend raises an important point, and it is a good one on which to end. Each of those three shifts—from hospital to community, from analogue to digital, and from sickness to prevention—could be taken in isolation. However, by putting them together, we can shift how we deliver health and care in this country. We will make it fit for purpose, we will drive up standards across the system, we will get the NHS back to constitutional standards—which means lower waiting times, shorter waiting lists and better outcomes—and, when it comes to cancer, we will save lives. It is as simple as that. Bill Presented Statutory Adoption Pay (Report on Extension to the Self-Employed) Bill Presentation and First Reading (Standing Order No. 57) Lisa Smart presented a Bill to require the Secretary of State to report to Parliament on the merits of extending eligibility for statutory adoption pay to persons who are self-employed or contractors; and for connected purposes. Bill read the First time; to be read a Second time on Friday 7 March , a nd to be printed (Bill 175).
4 Feb 2025 · National Cancer Plan · Hansard source
More
That kind of experience is unacceptable, and the purpose of our plan is to demand better of the NHS and the system more widely when it comes to cancer outcomes. Nobody should have the kind of experience that the hon. Lady’s constituent had, which is why we will drive better outcomes through better treatment and earlier diagnosis, and make sure that the whole NHS is joined up in the process—a key part of the national cancer plan.
4 Feb 2025 · National Cancer Plan · Hansard source
More
The hon. Member makes a reasonable point, and part of the reason that we are having a refreshed workforce plan alongside the 10-year NHS plan is precisely to address some of the concerns that he has raised. We need to make sure that we have the right workforce in the right place, and to future-proof it for the kinds of treatments that will come on stream in the coming decade.
4 Feb 2025 · National Cancer Plan · Hansard source
More
I thank my hon. Friend. I always call him my hon. Friend because I see more of him than I see of my wife. [ Laughter. ] Usually because we are in the same debates. The hon. Member makes an important point about research, which will be a crucial aspect of the national cancer plan. Advances in technology, science and pharmaceuticals do not happen by accident; they happen because we fund the research to get to that point. We need to do much better in researching some of the rarer and less survivable cancers. Those scientists and charities must have access to the funds that are available so they can carry out the research we need. As for where the 30 sites will be, that is above my pay grade. There are criteria, but I will take it back to my officials and see what we can do.
4 Feb 2025 · National Cancer Plan · Hansard source
More
I am very grateful to my hon. Friend for all the work that she has done on ovarian cancer since becoming an MP. She knows—the rest of the House might not—that I lost my mum to ovarian cancer. I was 19 when my mum died and she was only 50—my age today. She had a late diagnosis. They basically opened her up to perform a hysterectomy and the cancer had spread all the way through her body. They sewed her back up and she died at the end of a hospital ward two days later in pain and agony. Having awareness of those symptoms is so important. My mum was fobbed off by her GP, because she worked in a shop and lifted boxes. She had a bad back and was bloated and so on. The GP said it was down to her work, rather than erring on the side of caution and getting her checked out. We must ensure that women today are heard by GPs and, more importantly, that we err on the side of caution and get people on to treatment.
4 Feb 2025 · National Cancer Plan · Hansard source
More
Part of our recovery plan is to ensure that we return the national health service to constitutional standards, not just in respect of cancer but across the board. We inherited a broken national health service and it is incumbent on this Government to fix it and make it fit for the future. Clearly, in areas such as my hon. Friend’s, the NHS needs to be doing much better when it comes to cancer outcomes and cancer treatments, and this plan and this Government will ensure that his local system gets all the support it needs.
4 Feb 2025 · Accessibility of Radiotherapy · Hansard source
More
I was just coming to that—the hon. Gentleman has obviously started to read my notes from a distance. I am aware that he met representatives of the previous Government to discuss the possibility of a satellite unit in his local area. The situation is the same now as it was then: it is the responsibility of the integrated care board, but if the hon. Gentleman thinks it would be helpful for us to have a meeting and see if we can push that case, my door is open. I absolutely recognise that people in that part of Cumbria would prefer to have those services closer to where they live. If we can impress that on his local ICB, let us see if we can make progress. The Government aim to ensure that each treatment centre is accessible to the highest possible number of patients, as well as easily reached by the staff who work there. That is another consideration—it is not just the patients who have to physically get to these units, but the staff. We recognise that for those in rural communities, machinery may not be available at their local hospital, meaning that the only option is travel to specialist centres to receive the best possible care. Radiotherapy service provision is agreed by local systems, and each patient’s care needs and treatment location are decided on a case-by-case basis by their clinicians. We are giving local systems greater flexibility and control, as they are best placed to understand and meet the needs of their communities, but to drive the national cancer plan forward, we have to tackle this postcode lottery and the deserts head-on. Accessibility is also about making sure that we have the right workforce available to deliver the treatment in the right places and at the right time. That is why the number of training places has increased, and it is why we are improving the quality of education for assistant practitioners, diagnostics and therapeutic radiographers. NHS England is also working to improve the retention of radiographers and radiologists through initiatives such as increasing investment in career development. By ensuring our workforce feels supported, we put ourselves in a better position to deliver the care that people need. Turning to investment in machines, I agree with the hon. Member for Westmorland and Lonsdale that we should be ambitious in our plans to ensure that patients are treated as quickly as possible. Lord Darzi’s report highlighted the scale of the challenge we face: under the previous Government, waiting times for treatment increased, and more than 30% of patients waited longer than 31 days for radical radiotherapy. In response to Lord Darzi’s findings, we have taken urgent action to get the NHS back on its feet. At the recent Budget, my right hon. Friend the Chancellor supported our commitment to end the backlogs by announcing £70 million of investment in new radiotherapy machines in 2025-26. Replacing older radiotherapy machines with newer, more efficient and more technically advanced ones will ensure that patients can be seen more quickly. By doing so, we will improve access and speed up cancer treatment. Making more advanced machines available means that patients will have fewer trips to receive their treatment. Hon. Members may be aware that NHS England has now allocated funding to trusts across the country to purchase the new radiotherapy machines with the £70 million investment. NHS England invited trusts to express interest in receiving funding to purchase a new machine. Allocation criteria focused on the age of the machine being replaced, the proportion of older machines in use in the trust and the trust’s performance on radiotherapy. We expect to fund at least 27 new machines, which should be available to treat patients by spring 2026. Those steps will ensure that we can improve cancer waiting times as soon as possible, helping us to put an end to the last Government’s neglect and underinvestment. I reassure the hon. Member for Westmorland and Lonsdale, and other hon. Members, that we will continue to make the case for additional funding, so that we can continue to upgrade machines and push the advances of the latest technological developments, for the benefit of patients with cancer. I turn to the national cancer plan. Beyond immediate actions, we know that bold reform is required to rise to the growing challenge that cancers of all types represent. Lord Darzi found that cancer survival in this country is worse than in comparable countries, and that improvement slowed greatly during the 2010s. To help us to develop more targeted actions, my right hon. Friend the Secretary of State has announced the development of a national cancer plan, which was the subject of the statement I gave in the House just a few hours ago. The overarching aim of the plan is to reduce the number of lives lost to cancer. It will detail how we will improve outcomes for cancer patients, ensuring that patients have access to the most effective treatments and technology, including radiotherapy. Today, we launched our national cancer plan call for evidence. We welcome views from all hon. and right hon. Members, as well as from clinicians, patients and their families—it is critical that we get the views of people who have lived experience of accessing cancer care—charities, researchers, members of the public and, of course, the excellent all-party parliamentary groups that champion cancer treatment and outcomes in this House. In closing, I thank the hon. Member for Westmorland and Lonsdale for bringing this crucial matter to the House. I thank hon. Members, whose contributions have, in the spirit of this year’s World Cancer Day, put places and people at the centre of care. I am pleased to assure hon. Members that we are undertaking both immediate actions and bold reforms to improve access to radiotherapy. There is a lot more that we need to do, and we will do it in partnership. This work is part of our effort to rebuild the NHS and deliver world-class cancer services for everybody—something that will always be a top priority for this Government and that is personal for me—so let’s get on and achieve it.
4 Feb 2025 · Accessibility of Radiotherapy · Hansard source
More
It is a pleasure to serve under your chairmanship, Sir John. I thank the hon. Member for Westmorland and Lonsdale (Tim Farron) for bringing this important debate to Parliament on World Cancer Day, and other Members for their contributions on this really important topic. I am happy to meet the hon. Member and his colleagues from the all-party parliamentary group on radiotherapy to discuss these issues further. I suspect that my diary is going to get busier, but I am more than happy to meet the hon. Member for Wokingham (Clive Jones) as well, to ensure that we get this aspect of the national cancer plan absolutely right. To answer one of the questions put by the shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), the national cancer plan will include radiotherapy—it would be odd if it did not, given the importance of radiotherapy—and I will work with Radiotherapy UK and others with an interest in this area. That is partly why we have launched our call for evidence today: to get the views and opinions of as many people and organisations as possible, so that we get the plan right. It has to be fit not just for 2025, but for 2035 and the years in between, so there is a lot of work to be done. We know that cancer patients are waiting too long for treatment. That is why we are taking immediate action to kick-start the recovery of the NHS with a commitment to cut waiting times that will benefit all, including those with cancer. In our 10-year plan for the NHS, we committed to return our national health service to constitutional standards, including on cancer. By investing in our workforce, a point made by several hon. Members, and allocating £70 million for new radiotherapy machines, we will reduce cancer waiting times and give more patients access to state-of-the-art treatments. Fixing the NHS also requires reform. This year, we will publish our 10-year health plan to help build a health service fit for the future and, as I have already mentioned, we are today announcing the launch of a call for evidence for a dedicated national cancer plan, another step towards unleashing our country’s potential as a world leader in saving lives from this deadly disease. I encourage everyone to have their say by responding to the national cancer plan call for evidence. I assure hon. Members that the priority of this Government is to ensure that radiotherapy is available quickly to those who need it. Radiotherapy is a crucial treatment for many cancer patients, as it can shrink tumours very effectively. Although the vast majority of the population are located within reasonable distance of where they would go for treatment, I am very aware that that is not always the case, particularly in rural communities. I can give a family example. My dad, who sadly died two years ago from a very rare and aggressive form of rectal cancer, benefited from superb treatment at the Christie in Manchester, which is our local cancer hospital. He had chemotherapy, immunotherapy and radiotherapy. The radiotherapy shrank his tumours, and that almost certainly gave him an extra two years of quality life with his family, including his great-grandson. I will forever be grateful that he received that. One day, though, we took him to the Christie and he got chatting to somebody who was also receiving radiotherapy. This is pertinent to the hon. Member for North Shropshire (Helen Morgan), who leads on these matters for the Liberal Democrats, because this person was from Shropshire. My dad is Salopian born—he was born in Shrewsbury and brought up in High Ercall, before being dragged to Manchester in the 1950s when my grandad got a job as the chief accountant at Manchester education committee—and they got talking. “You’re really from Shropshire and you’re coming to Manchester for radiotherapy?” It was the nearest place that had that treatment available at that time. It really hit me then how sporadic these things are, and how some people have to travel unacceptably long distances. We need to make sure that in our national cancer plan, we look at the deserts and the accessibility issues.
4 Feb 2025 · Accessibility of Radiotherapy · Hansard source
More
I suspect that my diary will be a little busier with the two requests from the hon. Member for Westmorland and Lonsdale (Tim Farron).
3 Feb 2025 · Draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 · Hansard source
More
That is my understanding—I look for inspiration if I am wrong—of the situation today. If that is not correct, I will ensure that the hon. Lady and members of the Committee are informed in writing. The impact on businesses is the impact on business as it stands now, but we want to grow the business and ensure that the ecosystem grows and that the life sciences sector is booming in this country, for all the reasons that I set out in my opening speech. In conclusion, by modernising our regulatory framework we will ensure that lifesaving treatments are accelerated by streamlined, efficient processes without compromising safety standards. The reforms will strengthen the UK’s position as a global leader in innovative clinical trials and help to get lifesaving, life-changing medicines to the people who most need them sooner. I am grateful to the shadow Minister for her support and to Members for considering the regulations today; I hope they will all join me in supporting them. Question put and agreed to.
3 Feb 2025 · Draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 · Hansard source
More
I beg to move, That the Committee has considered the draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024. It is a pleasure to serve under your chairmanship, Sir Desmond. I am grateful for the opportunity to debate these important amendments, which represent the most significant reform of UK clinical trials regulation in more than 20 years. Clinical research is the single most important way in which we improve our healthcare, by identifying the best way to prevent, diagnose and treat conditions. Clinical trials are vital for patients with limited available treatment options, such as the estimated 3.5 million people living with rare diseases in the UK, together with the 17.5 million living with long-term conditions. This draft legislation will play a vital role in supporting the development of new treatments for those who so desperately need them by transforming the environment for clinical trials in the UK. The changes respond to the sector’s need for a more efficient and adaptable regulatory framework, while safeguarding the wellbeing of trial participants. The reforms will establish a proportionate, flexible and effective clinical research environment, placing patients at the heart of the process. The changes have been carefully designed in response to calls for reform, aligning with the direction set in our manifesto promise to build an NHS fit for the future and maximising the UK’s potential to lead the world in clinical trials. The reforms are further underpinned by the findings of Lord Darzi’s independent investigation of the NHS in England and the recommendations of Lord O’Shaughnessy’s review into commercial UK clinical trials. These changes to modernise the regulatory framework will cement the UK as a destination for clinical trials that is innovative, inclusive and international and will, most importantly, help to get life-changing medicines to the people who need them sooner. Let me explain to the Committee why Government believe change is needed. It is necessary and timely. The existing legislation is based on the now repealed and replaced European Union clinical trials directive. It no longer reflects the rapid advancements in medicine and technology. We have the opportunity to reform our national regulations to deliver a world-class regulatory environment for clinical trials, supporting the safe development of innovative treatments benefiting patients and public health alike. I will now briefly summarise the key aspects of the reforms. Of the key changes, the first is risk-proportionate regulation. Regulatory requirements will align with the risk level of a clinical trial, empowering researchers to adopt appropriate approaches. Low-risk clinical trials will benefit from faster approval processes through automatic authorisation, without compromising patient safety. Secondly, there is future-proofing: the draft legislation is a purposeful move away from a one-size-fits-all approach, which does not reflect modern, innovative clinical trial methods. We have removed granular and duplicative legal requirements in favour of specific, tailored guidance, which will provide flexibility and adaptability for future advancements. Thirdly, there is international alignment: the United Kingdom will remain aligned with international standards to ensure that data from UK trials is accepted globally. That will help to secure the UK’s place as a preferred site for multinational clinical trials, including those conducted across the European Union. Fourthly, this new framework will cement the UK as a destination for international clinical trials. Streamlined and efficient processes will be introduced to simplify clinical trial applications. The legislation will include a combined regulatory and research ethics review, ensuring that approval timelines are internationally competitive. Finally, there is increased transparency. We want to ensure that trusted information about clinical trials is publicly available for the benefit of all. The changes will, for the first time, introduce a legal requirement to register a clinical trial and to publish a summary of the results. Participants will be offered an easy-to-understand summary of what the research has found out. These new transparency requirements will build public trust in research, and ensure that participants, and the wider public, have access to information about ongoing research and can use research findings to help to make informed decisions. I will now turn to the benefits of this new framework in more detail. Patients will have greater access to life-changing treatments, which will improve outcomes and save lives. These reforms ensure that UK patients will be among the first to benefit from cutting-edge therapies. The transparency requirements will ensure that trusted information about clinical trials is publicly available for the benefit of all, improving public trust and confidence in the innovative clinical trials taking place in our country. Evidence also shows that hospitals that undertake research have better patient care outcomes and improved staff retention, and that it benefits the whole health and care system. Clinical trials are part of the solution for reducing the strain on our National Health Service. Improved efficiency in conducting clinical trials will enhance research efforts and foster innovation in prevention, diagnosis and treatment across various conditions. Additionally, we are broadening the categories of healthcare professionals who can be accepted as investigators, encouraging more researchers to carry out clinical trials in their specialist areas. Innovators and industry will run clinical trials within a streamlined, risk-proportionate regulatory framework, with reduced delays and administrative burdens, which will support industry growth and bolster the UK’s life sciences sector—something that I am sure Members on both sides of the House support. The impact on businesses has been evaluated; as the projected costs and benefits to businesses was below £5 million in any single financial year, a full impact assessment was not required, as originally stated in the accompanying explanatory notes. Instead, a de minimis assessment was produced and is published alongside this instrument. To summarise, this new framework uses effective regulation to accelerate the development of medicines, turning tomorrow’s emerging medicines into today’s reality for patients. By modernising our approach, we can solidify the United Kingdom’s position as a global leader in clinical research, fostering innovation while upholding the highest safety standards. I want to end on a critical point: participant safety remains paramount. This new legislation, while streamlining processes and removing unnecessary barriers to innovation, prioritises robust oversight of clinical trials, ensuring that the safety of those participating in a trial is never compromised. I therefore commend these draft regulations to the Committee, and I hope that hon. Members will join me in supporting these transformative changes.
3 Feb 2025 · Draft Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 · Hansard source
More
I thank the shadow Minister for her support for this piece of secondary legislation, which marks the most substantial update to UK clinical trial regulations in more than two decades. This is an important step forward to deliver a more efficient and adaptable regulatory framework, all while ensuring the safety of the trial participants. The reforms will deliver a proportionate, flexible and efficient clinical research environment, with patients at the very heart of the process. The shadow Minister raised the issue of AstraZeneca and the support for life sciences in the UK. Without straying too much from the measures before us, Sir Desmond, I want to reassure the Committee that this Government are fully committed to supporting the UK’s life sciences sector. Today we have heard about how vital clinical trials are in driving the health and wealth of the UK. The sector has experienced strong growth in recent years; between 2022 and 2023, the number of UK industry-led clinical trials increased by 3.7%. The UK has also gone up in the global rankings for phase 2 trials, moving from sixth to fourth place. That progress is a testament to our thriving research ecosystem, something that was developed under the previous Government and that we want to build on, which is what this set of regulations is all about. They are about making sure that our country is at the cutting edge of the latest developments in medical science and that British patients are able to access those treatments as early as possible, through clinical trials and then through the early adoption of those medicines once they are brought to market. The shadow Minister asked about the de minimis assessment. An assessment of the updated legislation has been produced, which estimates that there will be a total transition cost of approximately £720,000 to business for organisations to familiarise themselves with and operationalise the changes. It is expected that the annual total benefit to businesses will be £1 million, primarily due to the changes in the approval processes. I sought to correct the record in my opening remarks because it had originally been anticipated that we would need to have the full assessment, but on closer scrutiny that is not necessary because of the reasons that I have just set out.
30 Jan 2025 · Tobacco and Vapes Bill (Sixteenth sitting) · Hansard source
More
First, I thank my hon. Friend the Member for Dartford for his thanks. It would be remiss of me not to pay tribute to the former Prime Minister. When we were debating clause 1—all those many, many moons ago—I said that it took a lot of political bravery for a Conservative Prime Minister not just to go as far as he did, but to announce it at Conservative conference. I know from some of my Conservative friends that it raised significant eyebrows within that conference hall, but it was the right thing to do. That is why the Labour Opposition supported this legislation in the last Parliament. We would have loved to have seen it taken through the wash-up procedure before the general election, but that was not part and parcel of the deal that was put. However, we are here today with this Bill, which includes many of the things that the shadow Minister wanted to have included in her Bill. What is transformative is that once what we have taken through Committee today—we have Report and Third Reading to go—gains Royal Assent, it will ensure that no child born after 2009 will legally be able to be sold tobacco products ever again. We are stopping that conveyor belt, as I have described it, for the tobacco industry, and through stop smoking services and support we are coming after the market share that they have protected. We are going to make sure that vapes are never promoted, advertised or displayed in a way that will encourage children to take up vaping. The Bill is a landmark and it is life-changing. In just 25 years’ time, if the Government’s impact assessment is correct, the smoking prevalence of people under the age of 30 will be near to zero. It started here, with this Bill. Well done, and thanks to all Members.
30 Jan 2025 · Tobacco and Vapes Bill (Sixteenth sitting) · Hansard source
More
I am grateful to the shadow Minister. We have been greatly entertained by her history lessons—I now know more about snuff than I ever wanted to. We have had tradition. We spent such an inordinate amount of time on clause 1: I thought we would never reach this stage. We were certainly not going like the clappers or supersonic at the start. I suspect that we have heard a large amount from ChatGPT— [ Interruption. ] Well, I think perhaps my hon. Friend the Member for City of Durham certainly did a good google.
30 Jan 2025 · Tobacco and Vapes Bill (Sixteenth sitting) · Hansard source
More
I am grateful to the shadow Minister for her new clause 7. It would require the Government to publish and consult on draft regulations relating to the registration and information requirements set out in clauses 95 and 98. It stipulates that these regulations must be published within two months of Royal Assent of the Bill, and that a report on a mandated call for evidence, including the response to the House of Commons Business and Trade Committee, must be laid before both Houses six months after Royal Assent. Again, I am sympathetic to the shadow Minister’s desire to move swiftly in this space, but as with her similar proposals relating to licensing, this new clause would place an unreasonable and impractical constraint on the Government. To draft and publish these regulations within two months of Royal Assent is simply not feasible, and the new clause does not reflect the required processes and stages for the development of proportionate, appropriate and well-considered regulations. Development of secondary legislation takes time, and the arbitrary timescales proposed would not enable effective policy development. The Bill imposes on the Secretary of State a statutory obligation to consult on the appropriate parties ahead of introducing any regulations on this issue. Through this process, we will be able to carefully consider views relating to the existing notification schemes for tobacco products and nicotine vapes, as well as to get views on how a future registration scheme might work, and, importantly, use that input to shape and draft the required regulations. Forcing the Government to proceed hastily with producing new legislation opens up the risk of creating flawed policy. Creating flawed policy creates clear risks, not least the potential for the Government’s work to be legally challenged. I know that that is not what the shadow Minister wants, so I therefore ask her not to push her new clause to a vote.
30 Jan 2025 · Tobacco and Vapes Bill (Sixteenth sitting) · Hansard source
More
Clauses 168 and 169 provide for the commencement of provisions in parts 1 to 4 and parts 5 to 8 respectively. Provisions in parts 1 to 4 come into force six months after the day the Bill is passed, with certain exceptions, including the regulation-making powers contained in parts 1 to 3, including powers to implement a licensing scheme, which will be commenced on the day the Bill is passed. Provisions to implement the smoke-free generation policy across the UK will come into force on 1 January 2027, when those born on 1 January 2009 turn 18 years old. Clause 168 also provides for the commencement of various other provisions that are specific to the devolved Governments, such as the provision to update the definition of a tobacco product in Scottish legislation. The remaining provisions in parts 1 to 4 will be commenced by regulations or by order. Provisions in part 5 of the Bill, which relate to product and information requirements, are regulation-making powers, so they come into force on the day the Bill is passed. The majority of the provisions in part 6, such as those that prohibit the advertising of products including vaping products, will come into force on such day as the Secretary of State may appoint by regulations. Provisions in part 7 will come into force on such days as the relevant national authority may appoint by regulations. That includes regulation-making powers to create additional smoke-free places, and making smoke-free places vape-free. These are standard clauses that are required for the implementation of measures in the Bill. I turn now to Government amendments 15 and 98, which stand in my name. These technical amendments to clause 168 have been tabled at the request of the Welsh Government and the Northern Ireland Executive. Government amendment 15 concerns powers for the Welsh Ministers to commence provisions in part 1 relating to the licensing of retail sales in Wales and the handing over of tobacco products, herbal smoking products, cigarette papers, and vaping and nicotine products, to under-age people. Government amendment 98 concerns equivalent powers for the Department of Health in Northern Ireland to commence provisions in part 3 relating to the extension of the retailer register and the licensing of retail sales in Northern Ireland. Some parts of the provisions will be commenced automatically by clause 168(2) where they provide powers for the Welsh Ministers or the Department of Health in Northern Ireland to make regulations. Therefore, the amendment makes it clear that the power for the Welsh Ministers or the Department of Health in Northern Ireland to commence provisions cannot be used on those provisions that have already been commenced. The amendment serves to align the drafting for Wales and Northern Ireland with the equivalent provisions for England in clause 168(4). For that reason, I encourage the Committee to support the Government amendments. Amendment 15 agreed to. Amendment made: 98, in clause 168, page 121, line 12, after “force” insert “(so far as not in force by virtue of subsection (2))”.— ( Andrew Gwynne.) Clause 168(2) brings the regulation-making powers under Part 3 into force on royal assent. This amendment indicates that the power of the Department of Health in Northern Ireland to bring certain provisions into force is subject to that and is intended to ensure consistency with the drafting in clause 168(4). Clause 168, as amended, ordered to stand part of the Bill. Clause 169 ordered to stand part of the Bill. Clause 170 Transitional provision

Published records only — not a full account of an MP’s work. How we work →